FDG PET in Prostate Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed, 50 citations in OpenAlex.

1. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
   Trial
2. Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.European radiology · 2014
   Trial
3. The effects of muscle exercise and bed rest on [18F]methylcholine PET/CT.European journal of nuclear medicine and molecular imaging · 2011
   Trial
4. Phase I/IIa clinical trial ofAnnals of nuclear medicine · 2026
   Article
5. Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study.Journal of translational medicine · 2023
   Article
6. Synthesis and Evaluation ofMolecules (Basel, Switzerland) · 2022
   Article
7. Beyond the Prognostic Value of 2-[Diagnostics (Basel, Switzerland) · 2022
   Review
8. PET Use in Cancer Diagnosis, Treatment, and Prognosis.Methods in molecular biology (Clifton, N.J.) · 2022
   Article
9. The Emerging Role of Next-Generation Imaging in Prostate Cancer.Current oncology reports · 2022
   Review
10. Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
11. GLUT1 expression in high-risk prostate cancer: correlation withProstate cancer and prostatic diseases · 2020
    Article
12. Incidentalomas of the prostate detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020
    Article
13. Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response.Frontiers in oncology · 2020
    Review
14. Radiolabelled Aptamers for Theranostic Treatment of Cancer.Pharmaceuticals (Basel, Switzerland) · 2018
    Review
15. The Utility of [Molecular imaging and biology · 2018
    Article
16. The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018
    Article
17. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.European journal of nuclear medicine and molecular imaging · 2017
    Review
18. Therapy assessment of bone metastatic disease in the era ofEuropean journal of nuclear medicine and molecular imaging · 2017
    Review
19. Utility of FDG-PET in clinical neuroendocrine prostate cancer.The Prostate · 2014
    Article
20. Molecular imaging of prostate cancer.Current opinion in urology · 2012
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.